Goldman Sachs lowered the firm’s price target on uniQure (QURE) to $38 from $56 and keeps a Neutral rating on the shares. uniQure shares fell about 50% after the FDA withdrew support for a BLA submission of AMT-130 in Huntington’s disease, citing insufficient evidence from the Phase 1/2 trial to establish efficacy, the analyst tells investors in a research note. The agency highlighted limitations in the study’s design and reliance on post-hoc comparisons to external controls. The regulatory path forward remains uncertain as uniQure seeks further FDA engagement under breakthrough therapy designation and awaits meeting minutes for clarification, Goldman says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target lowered to $70 from $110 at H.C. Wainwright
- William Blair downgrades uniQure on uncertain path forward
- uniQure downgraded to Market Perform from Outperform at William Blair
- uniQure price target lowered to $53 from $76 at Chardan
- uniQure price target lowered to $45 from $65 at RBC Capital